ClinicalTrials.gg
CompletedNCT03245437Updated Nov 3, 2026Results posted

Target Engagement and Response to Oxytocin

A Phase 4 interventional study of Oxytocin nasal spray and Social Cognition Skills Training in Schizophrenia, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of California, Los Angeles · Phase 4, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing oxytocin in Schizophrenia — none open to participants now, 1 under way, none of them phase 3. Oxytocin · Schizophrenia.

Enrollment
11th of 31
59 · median 43
Started
2018
with 1 other
Phase 4
2 of 31
none open now
Registered
25th of 31
by date
Lead sponsor
2 of 31
University of California, Los Angeles

Among the 31 studies testing oxytocin in Schizophrenia, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 4, and was the 25th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 31 studies testing oxytocin in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About oxytocin

Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 31 studies testing oxytocin in Schizophrenia as a file.
02

Study summary

This study will measure whether the engagement of intranasal oxytocin with a brain target is related to effects on learning during a social cognition training program.

Read the detailed description

The study will determine whether oxytocin (OT) administration 30 min before a training session enhances the learning of social information in the context of a social cognitive skills training (SCST) program, and it will test a possible mediator of this effect. Subjects with psychotic disorders will be randomized to one of four groups in a 2 by 2 factorial design: OT with SCST; Placebo with SCST; OT with training control condition; placebo with training control condition. Target engagement will be measured in an OT challenge (placebo versus OT one week apart) prior to baseline assessment. The measure of target engagement will be EEG mu suppression while observing biological motion. A social cognition battery will be administered at baseline, at midpoint after 6 weeks of SCST, and at completion of training at 12 weeks. The battery will include measures of social cue identification and mentalizing.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Social Cognition
  • Oxytocin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Schizophrenia or schizoaffective disorder
  • stable on an antipsychotic medication

Exclusion criteria

Exclusion Criteria:

  • positive pregnancy test history of head injury
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Oxytocin with SCST

    Oxytocin with SCST (active condition)

    Drug: Oxytocin nasal spray · Behavioral: Social Cognition Skills Training

  • Sham comparator
    Oxytocin with Health Management

    Administration of OT with control psychosocial treatment

    Drug: Oxytocin nasal spray · Behavioral: Health Management

  • Placebo comparator
    Placebo with SCST

    Administration of Placebo with active psychosocial treatment

    Behavioral: Social Cognition Skills Training · Drug: Placebo nasal spray

  • Placebo comparator
    Placebo with HM

    Administration of Placebo with control psychosocial treatment

    Behavioral: Health Management · Drug: Placebo nasal spray

Interventions

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    nasal spray

    Also known as: OT

  • BehavioralSocial Cognition Skills Training

    Group based training in social cognition skills

    Also known as: SCST

  • BehavioralHealth Management

    Group-based training in mental health management

    Also known as: HM

  • DrugPlacebo nasal spray

    placebo condition

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Social Cue Identification

    Social cue identification is a composite score created for this study of the Emotion Identification Test from the Ekman Program (Ekman) and the Profile of Nonverbal Sensitivity (PONS). People use information from identifying emotions on faces and other nonverbal cues to assess an individual's ability to identify social cues. The primary summary measure for each test (Ekman, PONS) is mean-centered and standardized to create a Z-score. The two Z-scores are then averaged to create Social Cue Identification. A Z-score standardizes data to a scale (a z-distribution with a mean of 0 and standard deviation of 1). Higher scores represent a better outcome. Ekman, P., Subtle Expression Training Tool (SETT) \& Micro Expression Training Tool (METT), 2004, Paul Ekman www.paulekman.com. Rosenthal R, Hall J, DiMatteo M, Rogers P, Archer D. Profile of nonverbal sensitivity (PONS test): Manual. Unpublished manuscript available from JA Hall, Northeastern University, Boston, MA 2011.

    Time frame: 16 weeks

  2. Social Cognition: Mentalizing

    Mentalizing is a composite measure of higher-order social cognition that assesses an individual's ability to understand the thoughts, intentions, beliefs, and experiences of others. The composite combines scores from The Awareness of Social Inference Test (TASIT) and the Empathic Accuracy Task. TASIT assesses the ability to infer others' intentions and beliefs from social interactions, and the Empathic Accuracy Task assesses the ability to accurately infer another person's emotional experiences. Raw scores from each measure were standardized to Z-scores and averaged to create the Mentalizing composite score: Mentalizing = mean(TASIT Total Z-score, Empathic Accuracy Z-score). A Z-score of 0 represents the sample mean. Positive Z-scores indicate better-than-average mentalizing ability, negative Z-scores indicate worse-than-average mentalizing ability. Higher Z-scores represent better performance. There are no established clinical thresholds for interpretation of this composite measure

    Time frame: 16 weeks

Secondary outcomes

  1. Non-Social Cognition

    The secondary outcome measure of Non-social cognition is based on the MATRICS Consensus Cognitive Battery (MCCB). The MCCB overall score is a composite score from the MATRICS that provides a standardized measure of an individual's global cognitive function, with a mean (SD) of 50(10) for a healthy control group. Higher scores indicate better cognitive function. The score is interpreted based on a T-score scale that accounts for age and sex.

    Time frame: 16 weeks

07

Results

Posted Nov 3, 2026
Limitations and caveats
We did not include any measures of central (e.g. EEG) or peripheral (e.g. plasma) oxytocin activity, so it is unclear to what extent variability in baseline oxytocin levels affected our results and how well the treatment was absorbed. We did not recruit a patient population with specific impairments in the social domains we tested, and it is possible that our population did not have sufficient impairments to show improvement with the intervention.

Participant flow

To meet our recruitment goals, patients with schizophrenia will be recruited from five sources: previous participants who have asked to be contacted for future studies by initialing this preference in a consent form from another study, participants of the MIRECC Treatment and Clinical Neuroscience Repository (Marder #0042), outpatient mental health clinics within the VA Greater Los Angeles Healthcare System (VAGLAHS), the UCLA Psychosis Clinic; and local board and care facilities.

Pre-Treatment/Randomization Assignment
Participant flow — Pre-Treatment/Randomization Assignment
MilestoneOT/SCSTOT/HMPbo/SCSTPbo/HM
Started16131218
Completed16111118
Not completed0210
Withdrew: Subject tested positive on urine drug screen for methanphetamine0100
Withdrew: Withdrew before baseline due to work/relocation0110
Treatment weeks 0-12
Participant flow — Treatment weeks 0-12
MilestoneOT/SCSTOT/HMPbo/SCSTPbo/HM
Started16111118
Completed1511914
Not completed1024
Withdrew: Lost to follow-up1001
Withdrew: Death0010
Withdrew: Adverse event0011
Withdrew: Withdrawal by subject0002
Post-treatment/ Follow-up
Participant flow — Post-treatment/ Follow-up
MilestoneOT/SCSTOT/HMPbo/SCSTPbo/HM
Started1511914
Completed1411914
Not completed1000

Outcome measures

SecondaryNon-Social Cognition

The secondary outcome measure of Non-social cognition is based on the MATRICS Consensus Cognitive Battery (MCCB). The MCCB overall score is a composite score from the MATRICS that provides a standardized measure of an individual's global cognitive function, with a mean (SD) of 50(10) for a healthy control group. Higher scores indicate better cognitive function. The score is interpreted based on a T-score scale that accounts for age and sex.

Time frame:
16 weeks
Reported as:
Least squares mean · Standard Deviations
Non-Social Cognition
Standard DeviationsOT/SCSTOT/HMPbo/SCSTPbo/HM
Non-Social Cognition38.2 ± 3.240.1 ± 3.940.9 ± 4.037.5 ± 3.2
Statistical analysis
  • OT/SCST vs OT/HM vs Pbo/SCST vs Pbo/HM · Mixed Models Analysis · p = 0.13
PrimarySocial Cue Identification

Social cue identification is a composite score created for this study of the Emotion Identification Test from the Ekman Program (Ekman) and the Profile of Nonverbal Sensitivity (PONS). People use information from identifying emotions on faces and other nonverbal cues to assess an individual's ability to identify social cues. The primary summary measure for each test (Ekman, PONS) is mean-centered and standardized to create a Z-score. The two Z-scores are then averaged to create Social Cue Identification. A Z-score standardizes data to a scale (a z-distribution with a mean of 0 and standard deviation of 1). Higher scores represent a better outcome. Ekman, P., Subtle Expression Training Tool (SETT) \& Micro Expression Training Tool (METT), 2004, Paul Ekman www.paulekman.com. Rosenthal R, Hall J, DiMatteo M, Rogers P, Archer D. Profile of nonverbal sensitivity (PONS test): Manual. Unpublished manuscript available from JA Hall, Northeastern University, Boston, MA 2011.

Time frame:
16 weeks
Reported as:
Least squares mean · Z-Score
Social Cue Identification
Z-ScoreOT/SCSTOT/HMPbo/SCSTPbo/HM
Week12 Endof Treatment0.13 ± 0.20.05 ± 0.20.86 ± 0.20.23 ± 0.2
Week 0 Start of Treatment-.23 ± .220.0045 ± 0.260.65 ± 0.260.067 ± 0.21
Statistical analysis
  • OT/SCST vs OT/HM vs Pbo/SCST vs Pbo/HM · Mixed Models Analysis · p = 0.54 (F-Test for three way interaction of Time, Treatment and Training Group F(1,101) = 0.38. p-value = 0.54)
PrimarySocial Cognition: Mentalizing

Mentalizing is a composite measure of higher-order social cognition that assesses an individual's ability to understand the thoughts, intentions, beliefs, and experiences of others. The composite combines scores from The Awareness of Social Inference Test (TASIT) and the Empathic Accuracy Task. TASIT assesses the ability to infer others' intentions and beliefs from social interactions, and the Empathic Accuracy Task assesses the ability to accurately infer another person's emotional experiences. Raw scores from each measure were standardized to Z-scores and averaged to create the Mentalizing composite score: Mentalizing = mean(TASIT Total Z-score, Empathic Accuracy Z-score). A Z-score of 0 represents the sample mean. Positive Z-scores indicate better-than-average mentalizing ability, negative Z-scores indicate worse-than-average mentalizing ability. Higher Z-scores represent better performance. There are no established clinical thresholds for interpretation of this composite measure

Time frame:
16 weeks
Reported as:
Least squares mean · points on a scale
Social Cognition: Mentalizing
points on a scaleOT/SCSTOT/HMPbo/SCSTPbo/HM
Week 12 End of Treatment0.0031 ± 0.210.19 ± 0.25-.026 ± 0.260.09 ± 0.21
Week 0 Start of Treatment-0.1199 ± 0.20990.08177 ± 0.2530.3165 ± 0.2531-.0772 ± .1985
Statistical analysis
  • OT/SCST vs OT/HM vs Pbo/SCST vs Pbo/HM · Mixed Models Analysis · p = 0.10
  • OT/SCST vs OT/HM vs Pbo/SCST vs Pbo/HM · Mixed Models Analysis · p = 0.10 (The analysis evaluated the three-way interaction of time, treatment, and training group using a mixed-effects model)The analysis evaluated the three-way interaction of time, treatment, and training group using a mixed-effects model

Adverse events

Collected over Adverse Events Collected from enrollment to end of trial (12 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OT/SCST0/16 (0%)0/16 (0%)5/16 (31.3%)
OT/HM0/13 (0%)0/13 (0%)4/13 (30.8%)
Pbo/SCST1/12 (8.3%)1/12 (8.3%)5/12 (41.7%)
Pbo/HM0/18 (0%)0/18 (0%)8/18 (44.4%)
Most frequent serious events
Most frequent serious events
EventOT/SCSTOT/HMPbo/SCSTPbo/HM
POSITIVE COVID-19Investigations0/160/131/120/18
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOT/SCSTOT/HMPbo/SCSTPbo/HM
ANXIETYPsychiatric disorders0/160/131/120/18
EPIPHORAEye disorders0/160/131/120/18
HEADACHENervous system disorders0/160/131/120/18
INSOMNIAPsychiatric disorders0/160/131/120/18
RUNNY NOSERespiratory, thoracic and mediastinal disorders0/160/131/120/18
COMMON COLDInfections and infestations0/161/130/120/18
GERDGastrointestinal disorders0/161/130/120/18
POSITIVE COVID-19Investigations1/161/130/121/18
TOOTH INFECTIONInfections and infestations0/161/130/120/18
BACK PAINMusculoskeletal and connective tissue disorders1/160/130/120/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
Mean42.7 ± 11.951.6 ± 8.747.8 ± 11.642.1 ± 12.745.2 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
Female232613
Male14891243
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
American Indian or Alaska Native00000
Asian00044
Native Hawaiian or Other Pacific Islander00000
Black or African American1076932
White634518
More than one race01102
Unknown or Not Reported00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
Hispanic or Latino11316
Not Hispanic or Latino151081750
Unknown or Not Reported00000
Emotion Identification Test from Ekman Program.
Emotion Identification Test from Ekman Program.(points on a scale)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
Mean42.1 ± 7.443.3 ± 3.749.3 ± 6.743.8 ± 6.944.18 ± 6.8
Profile of Nonverbal Sensitivity
Profile of Nonverbal Sensitivity(points on a scale.)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
Mean75.6 ± 8.179.8 ± 6.581.4 ± 6.279.8 ± 5.378.9 ± 6.8
The Awareness of Social Inference Test (TASIT).
The Awareness of Social Inference Test (TASIT).(Percent)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
Mean46.6 ± 8.647.1 ± 7.949 ± 8.346.2 ± 8.147.0 ± 8.1
The Empathic Accuracy Task.
The Empathic Accuracy Task.(Correlation coefficient)OT/SCSTOT/HMPbo/SCSTPbo/HMTotal
Mean0.6 ± 0.20.6 ± 0.10.6 ± 0.20.6 ± 0.10.6 ± 0.1

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • UCLA
    Los Angeles, California 90073, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data from this study have been submitted to the National Data Archive https://nda.nih.gov/ under collection number C2305. Researchers may request access via the website. Item level data from study measures are available to researchers. A complete list of data available can be found on the NDA website.

Time frame: Data are already shared under Collection id C2305 via the National Data Archive https://nda.nih.gov/. Further information can be found on the website or by emailing NDAHelp@mail.nih.gov.

Access criteria: Information on data access can be found here: https://nda.nih.gov/user/dashboard/data_permissions

Data sharing details ↗ · nda.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jul 2024, 78 months.

Results were first posted in Nov 2026, 2 years 3 months after primary completion.

Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's 78 months is above that.

Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2017
First posted
Aug 10, 2017
StartActual
Jan 4, 2018
Primary completionActual
Jul 31, 2024
CompletionActual
Jul 31, 2024
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Enrollment
120→59
Nov 3, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedSocial Cognition Composite Score: MentalizingTime frame: 16 weeks
  • AddedSocial Cue IdentificationTime frame: 16 weeks
Nov 3, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Composite score of non-social cognition from the MATRICS Consensus Cognitive BatteryNow Non-Social CognitionTime frame: 16 weeks
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Enrollment 120→59
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedSocial Cognition Composite Score: MentalizingTime frame: 16 weeks
    • AddedSocial Cue IdentificationTime frame: 16 weeks
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Composite score of non-social cognition from the MATRICS Consensus Cognitive BatteryNow Non-Social CognitionTime frame: 16 weeks
    + 5 other changes: index terms, verification date, registry dates, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03245437
Responsible party
Stephen R. Marder (Professor, University of California, Los Angeles) — Principal investigator
First posted
Aug 10, 2017
Start date
Jan 4, 2018
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Stephen Marder, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion